Researchers track rare bone disease over years in observational study
NCT ID NCT04783428
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 23 people with tumor-induced osteomalacia (TIO), a rare condition where tumors cause weak bones. The goal is to see how well the drug burosumab works over time and to monitor any tumor changes. Participants continue their usual care, and no new treatments are given.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TUMOR-INDUCED OSTEOMALACIA (TIO) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
IDIM - Instituto de Diagnóstico e Investigaciones Metabólicas
Buenos Aires, Argentina
-
Indiana University
Bloomington, Indiana, 47405, United States
-
Johns Hopkins University
Baltimore, Maryland, 21218, United States
-
University of Virginia
Charlottesville, Virginia, 22908, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37235, United States
-
Yale University
New Haven, Connecticut, 06520, United States